[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allogeneic-hematopoietic-stem-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allogeneic-hematopoietic-stem-cell-transplantation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,40,69,96,124,153,182,211,232,263,289,316,341,368,390,408,432,452,476],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100644120","younger-vs-older-donors-in-allo-hsct-tte-100644120",false,"NCT07666568","Younger vs. Older Donors in Allo-HSCT: TTE","Prognostic Comparison of Allogeneic Hematopoietic Stem Cell Transplantation Using Younger Versus Older Donors: A Target Trial Emulation Study","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosis of hematologic malignancy.\n* Underwent first allogeneic hematopoietic stem cell transplantation.\n* HLA matching level of 0.5 or higher.\n* Available donor age information.\n* Available clinical follow-up and outcome data.\n\nExclusion Criteria:\n\n* Previous autologous or allogeneic hematopoietic stem cell transplantation.\n* HLA matching level below 0.5.\n* Missing donor age information.\n* Missing key exposure-defining or outcome-defining data required for the analysis.","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","Hematopoietic stem cell transplantation is an important therapeutic approach for hematologic malignancies, and the impact of donor age on transplant outcomes remains an active area of investigation. Older donors may be associated with impaired stem cell fitness, delayed immune reconstitution, and reduced T-cell function. However, randomized controlled trials directly comparing transplant outcomes by donor age are difficult to conduct because of ethical constraints, and previous retrospective studies have yielded inconsistent findings due to confounding bias and limited causal interpretability. Target trial emulation (TTE) is a methodological framework that uses observational data to emulate the design principles of a randomized trial, thereby reducing biases such as immortal time bias, time-varying confounding, and prevalent-user bias, and improving the validity of causal inference. Therefore, this study will use a large single-center retrospective clinical cohort to perform a TTE analysis, aiming to approximate the causal framework of an randomized trial and systematically evaluate the effect of donor age on clinical outcomes after allo-HSCT, thereby providing higher-quality evidence to optimize donor selection strategies.",[24,25,26],"A Target Trial Emulation Study","Donor Age","ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION","NOT_YET_RECRUITING","2026-06-22",{"date":30,"type":31},"2026-06-24","ACTUAL",{"date":33,"type":20},"2026-07-15",{"date":35,"type":20},"2027-12-21",{"name":37,"class":38},"The First Affiliated Hospital of Soochow University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":39},"100314790","early-phase-1-antigen-specific-adoptive-t-cell-therapy-for-adenovirus-infection-after-hematopoietic-stem-cell-transplantation-100314790","NCT03378102","Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation","Antigen Specific Adoptive T Cell Therapy for Refractory Opportunistic Adenovirus Infection After a Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patients must have received allogeneic HSCT and be greater than 30 days post-HSCT at the time of registration.\n* Patients must have evidence of documented HAdV infection\u002Freactivation. Patients may be:\n\n  * Symptomatic with any detectable viral load OR\n  * Asymptomatic with viral load that is:\n\n\\>1000 copies\u002Fml in peripheral blood OR qualitative detection in stool, urine and\u002For other specimens\n\n* Patients must have poor response and\u002For contraindication to therapy:\n\n  * Absence of an improvement of viral load (decrease by at least 1 log, i.e. 10-fold) after ≥ 14 days of antiviral therapy with ganciclovir, valganciclovir and\u002For foscarnet. OR\n  * New, persistent and\u002For worsening HAdV-related symptoms, signs and\u002For markers of end organ compromise while on antiviral therapy with ganciclovir, valganciclovir or foscarnet. OR\n  * Have contraindications or experience adverse effects of antiviral therapy with ganciclovir, valganciclovir, cidofovir or foscarnet.\n* Performance Score: Eastern Cooperative Oncology Group (ECOG) Performance Score ≤ 3. Karnofsky (≥ 16 years) or Lansky (\\\u003C16 years) performance score ≥ 50\n* The effects of virus-specific, antigen-selected T cells on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry, for the duration of study participation and for 3 months after completing treatment.\n* Subjects who are 14 years and older must have the ability to understand and the willingness to sign a written informed consent document, or assent document.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women are excluded from this study. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with the agents described above, breastfeeding should be discontinued if the mother participates in this trial.\n* Patients with opportunistic viral infections other than HAdV.\n* Patients with active, grade II-IV, acute graft versus host disease (GVHD), chronic GVHD or any condition requiring high doses of glucocorticosteroid (\\>0.5 mg\u002Fkg\u002Fday prednisone or its equivalent) as treatment.\n* Treatment with antithymocyte globulin within 28 days of planned infusion of virus - specific, antigen selected T cells.\n* Treatment with virus - specific T cells within 6 weeks (42 days) of planned infusion.","3 Months",{"count":49,"type":20},20,"INTERVENTIONAL",[52],"EARLY_PHASE1","The purpose of this study is to determine if it is possible to treat an infection with a cell-based immunotherapy (therapy that uses the patient's own immune system to treat the infection). This treatment is called adoptive T cell therapy. Another purpose is to learn about the side effects and toxicities of adoptive T cell therapy.\n\nAdoptive T cell therapy is an investigational (experimental) therapy that works by using the blood of a donor that has immunity against the virus. The donor cells are collected and then the cells, called T cells, that are capable of defending against the virus are selected out. These selected T cells are then infused back into the patient, to try to give the immune system the ability to fight the infection. Adoptive T cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).",[55],"Allogeneic Hematopoietic Stem Cell Transplantation",[57,58],"T Cell Therapy","Opportunistic Infection","RECRUITING","2026-06-03",{"date":62,"type":31},"2026-06-04",{"date":64,"type":31},"2019-01-04",{"date":66,"type":20},"2028-12",{"name":68,"class":38},"Mari Dallas",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":50,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":39},"100636975","phase-2-moxibustion-for-steroid-refractory-acute-graft-versus-host-disease-after-allogeneic-hematopoietic-stem-cell-transplantation-100636975","NCT07572669","Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","A Prospective, Multicenter, Open-Label, Phase II Study to Evaluate the Safety and Efficacy of Moxibustion in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\nAge 14 to 65 years, male or female. Underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Diagnosis of acute graft-versus-host disease (aGVHD) according to standard criteria, with gastrointestinal involvement (e.g., abdominal pain and diarrhea), and classified as grade II-IV.\n\nSteroid-refractory or steroid-dependent aGVHD, defined as:\n\nDisease progression within 3 days of systemic corticosteroid treatment, or No response within 7 days, or Failure to achieve complete response after 28 days of immunosuppressive therapy, or Recurrence or worsening during steroid tapering. Absolute neutrophil count ≥ 0.5 × 10⁹\u002FL for at least 3 consecutive days. Traditional Chinese medicine (TCM) syndrome differentiation consistent with spleen-kidney yang deficiency.\n\nFemale participants of childbearing potential must have a negative pregnancy test at screening and agree to use effective contraception during the study.\n\nMale participants must agree to use effective contraception during the study. Ability to understand and willingness to sign a written informed consent form. Willingness and ability to comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\nPrior treatment with ≥1 systemic therapy for aGVHD other than corticosteroids. Diagnosis of GVHD overlap syndrome according to NIH criteria. History of splenectomy after transplantation. Evidence of relapse of the underlying disease or receipt of anti-relapse therapy after transplantation.\n\nUnresolved toxicities or complications from prior transplantation (excluding GVHD).\n\nPrior moxibustion therapy after transplantation. Uncontrolled active infection. Known human immunodeficiency virus (HIV) infection. Active hepatitis B or C infection requiring treatment, or risk of HBV reactivation.\n\nReceipt of other investigational therapy within 21 days prior to enrollment (or within 5 half-lives, whichever is longer).\n\nRenal dysfunction: serum creatinine ≥ 2.0 mg\u002FdL or creatinine clearance \\\u003C 40 mL\u002Fmin.\n\nHepatic dysfunction unrelated to GVHD, including cholestatic disease or unresolved hepatic veno-occlusive disease.\n\nSevere cardiovascular disease, including unstable angina, myocardial infarction within 6 months, NYHA class III-IV heart failure, or circulatory failure requiring vasoactive support.\n\nSevere respiratory disease requiring mechanical ventilation or ≥50% oxygen support.\n\nUse of high-dose corticosteroids (≥1 mg\u002Fkg\u002Fday methylprednisolone or equivalent) for non-GVHD indications within 7 days prior to enrollment.\n\nPregnant or breastfeeding women. Severe skin damage or known allergy\u002Fintolerance to study-related procedures. Any other condition that, in the investigator's judgment, would interfere with study participation.","14 Years","65 Years",{"count":79,"type":20},42,[81],"PHASE2","This study is a prospective, multicenter, open-label, phase II clinical trial designed to evaluate the safety and efficacy of moxibustion in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT).\n\nA total of 42 patients with SR-aGVHD, primarily involving the gastrointestinal tract and presenting with abdominal pain and diarrhea, will be enrolled. All participants will receive standard second-line therapy based on best available treatment (BAT), including ruxolitinib, basiliximab, or methotrexate, according to clinical judgment. In addition, patients will receive moxibustion at specific acupoints (Tianshu \\[ST25\\], Shenque \\[CV8\\], and Qihai \\[CV6\\]) for 30 minutes once or twice daily for 28 days.\n\nThe primary endpoint is the overall response rate (ORR) at Day 28. Secondary endpoints include durable ORR at Day 56, incidence and severity of chronic GVHD (cGVHD), non-relapse mortality (NRM), overall survival (OS), and changes in traditional Chinese medicine (TCM) syndrome scores. Safety will be assessed by monitoring adverse events throughout the study period.\n\nThis study aims to explore whether moxibustion, as an adjunctive therapy, can improve clinical outcomes and provide a safe and effective treatment strategy for patients with SR-aGVHD after allo-HSCT.",[84,85,86,55],"Steroid-Refractory Acute Graft-Versus-Host Disease","Acute Graft-Versus-Host Disease","Graft-Versus-Host Disease","2026-05-03",{"date":89,"type":31},"2026-05-07",{"date":91,"type":31},"2025-09-01",{"date":93,"type":20},"2027-09",{"name":95,"class":38},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":50,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":39},"100634127","phase-1-baricitinib-for-post-hsct-persistent-thrombocytopenia-100634127","NCT07535645","Baricitinib for Post-HSCT Persistent Thrombocytopenia","Safety and Efficacy of Baricitinib in Thrombopoietin-Receptor-Agonist-Refractory Persistent Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation: A Phase Ib\u002FII Study","BAPT","Inclusion Criteria:\n\n* Aged 18-70 years;\n* Underwent allo-HSCT;\n* Meet the diagnostic criteria for delayed platelet engraftment (DPE) or secondary failure of platelet recovery (SFPR);\n* Have platelet counts consistently \\\u003C20 ×10\\^9\u002FL or transfusion-dependent within 14 days prior to enrollment;\n* Have received adequate corticosteroid and TPO-RA therapy for persistent thrombocytopenia for no less than 4 weeks, with treatment failure or intolerance;\n* Complete donor chimerism.\n\nExclusion Criteria:\n\n* Relapse of hematologic malignancy or MRD positivity;\n* Active infection;\n* Active graft-versus-host disease;\n* Thrombotic microangiopathy;\n* Primary graft failure or poor graft function;\n* Presence of other factors that may lead to secondary thrombocytopenia at the time of PT diagnosis;\n* History of systemic herpes zoster infection within 12 weeks prior to enrollment screening;\n* Acute or chronic infection with HBV, HCV, or HIV;\n* Evidence of active tuberculosis, or history of active tuberculosis without documented standard anti-tuberculosis treatment, or close contact with active tuberculosis without documented standard tuberculosis prophylaxis;\n* Receipt of a live vaccine within 12 weeks prior to enrollment screening, or planned receipt of a live vaccine during the study period;\n* Clinically significant thromboembolic event within 24 weeks prior to enrollment screening, or current use of anticoagulant medications deemed by the investigator to carry an uncontrollable risk;\n* Estimated glomerular filtration rate \\\u003C50 mL\u002Fmin\u002F1.73 m\\^2;\n* Severe pre-existing or current conditions involving the cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, nervous, or neuropsychiatric systems, or other severe or unstable illnesses or laboratory abnormalities that will make the study drug unacceptable for the patient or can interfere study data;\n* Participation in another clinical trial within 30 days prior to enrollment.","70 Years",{"count":106,"type":20},28,[108,81],"PHASE1","This is a prospective, open-label phase 1b\u002F2 clinical trial to explore the safety and efficacy profiles of baricitinib in patients with thrombopoietin-receptor-agonist-refractory persistent thrombocytopenia after allogeneic hematopoietic stem cell transplantation.",[111,55],"Persistent Thrombocytopenia",[113,55,114],"Persistent thrombocytopenia","Baricitinib","2026-04-14",{"date":117,"type":31},"2026-04-17",{"date":119,"type":20},"2026-04-15",{"date":121,"type":20},"2029-09-15",{"name":123,"class":38},"Peking University People's Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":50,"phases":135,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100577754","nutrition-outreach-in-systems-of-healthcare-100577754","NCT06802406","Nutrition OUtReach In Systems of Healthcare","NOURISH","Inclusion Criteria:\n\n* Planning to receive transplant or cell therapy\n* Screen positive for food insecurity by answering \"often true\" or \"sometimes true\" to one of the following:\n\n  * \"Within the past 12 months, you worried that your food would run out before you got money to buy more,\"\n  * \"Within the past 12 months, the food you bought just didn't last and you didn't have money to get more.\"\n* Age 8 - 80\n* Able to read\u002Fwrite English or Spanish (many patient-reported outcome measures lack validated translations in other languages)\n\nExclusion Criteria:\n\n* Patients who do not tolerate oral nutrition at the time of study enrollment","8 Years","80 Years",{"count":134,"type":20},210,[136],"NA","Many children and adults receiving medical treatments have higher costs, which can make it harder for them to afford groceries. When someone can't afford enough food, and they do not receive proper nutrition it can make treatment more difficult.\n\nBy doing this study investigators hope to learn more about whether addressing food insecurity by giving patients bags of food in clinic can help improve nutrition, reduce costs, and improve transplant and cellular therapy outcomes.",[26,139,140,141],"Autologous Haemopoietic Stem Cell Transplant","CAR-T Cell Therapy","Food Insecurity",[143],"nutrition, food insecurity",{"date":145,"type":31},"2026-04-20",{"date":147,"type":31},"2025-05-01",{"date":149,"type":20},"2029-05",{"name":151,"class":38},"University of Kansas Medical Center",4,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":50,"phases":163,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100623426","phase-3-fludarabine-plus-melphalan-versus-addition-of-venetoclax-to-fludarabinemelphalan-conditioning-regimen-for-allogeneic-hematopoietic-stem-cell-transplantation-in-amlmds-patients-aged--50-years-a-multicenter-randomized-phase-3-trial-100623426","NCT07396480","Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine\u002FMelphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML\u002FMDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","Inclusion Criteria:\n\n1. Aged \\> 50 years;\n2. Confirmed as acute myeloid leukemia (AML) in remission prior to transplantation, myelodysplastic syndrome (MDS; IPSS: Intermediate-2, high; or IPSS-R: Intermediate, high, very high; or IPSS-M: moderate-high, high, and very high), or myelodysplastic syndrome\u002Fmyeloproliferative neoplasm (MDS\u002FMPN) by morphology, immunology, cytogenetics and molecular biology (MICM) typing;\n3. Having an eligible donor and scheduled to undergo allogeneic hematopoietic stem cell transplantation (Allo-HCT) from a related or unrelated donor;\n4. Karnofsky Performance Score ≥ 70;\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status \\\u003C 3;\n6. Expected survival time \\> 12 weeks;\n7. Voluntarily signing the informed consent form and being able to understand and comply with all study requirements.\n\nExclusion Criteria:\n\n1. Complicated with severe cardiac insufficiency with a left ventricular ejection fraction (EF) \\\u003C 60%; or complicated with severe arrhythmia, and assessed by the investigator as unable to tolerate the intensive conditioning regimen;\n2. Complicated with severe pulmonary insufficiency (obstructive and\u002For restrictive ventilatory disorder), and assessed by the investigator as unable to tolerate the intensive conditioning regimen;\n3. Complicated with severe liver function impairment, with liver function indicators (alanine aminotransferase \\[ALT\\], total bilirubin \\[TBIL\\]) exceeding 3 times the upper limit of normal (ULN); and assessed by the investigator as unable to tolerate the intensive conditioning regimen;\n4. Complicated with severe renal insufficiency, with serum creatinine (Cr) exceeding 2 times the upper limit of normal (ULN); or with a 24-hour creatinine clearance rate (Ccr) \\\u003C 50 ml\u002Fmin, and assessed by the investigator as unable to tolerate the intensive conditioning regimen;\n5. Suffering from severe active infection prior to transplantation, and assessed by the investigator as unable to tolerate the intensive conditioning regimen;\n6. Having a history of allergic reactions or severe adverse reactions to the drugs involved in the conditioning regimen, and assessed by the investigator as ineligible for enrollment;\n7. Other reasons for ineligibility assessed by the investigator.","50 Years","75 Years",{"count":162,"type":20},186,[164],"PHASE3","Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) serves as a curative treatment modality for the vast majority of patients with hematological malignancies. Historically, due to the relatively high treatment-related mortality rate associated with Allo-HCT, this therapy was primarily administered to younger patients. However, the median age at onset of most hematological malignancies falls within the elderly population. For instance, the median ages at onset of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) are 68 and 77 years, respectively. In recent years, with the advancement of transplantation techniques and the application of Reduced-intensity Conditioning (RIC) regimens, a growing number of elderly patients have undergone Allo-HCT. Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) indicate that in 2017, 31% of patients who received Allo-HCT were aged over 60 years, and 6% were over 70 years old. Over the past decade, the number of elderly patients undergoing Allo-HCT has increased significantly.\n\nGiven that most elderly patients cannot tolerate conventional myeloablative conditioning regimens, RIC regimens based on Fludarabine (Flu) combined with Busulfan (Bu), or Fludarabine (Flu) combined with Melphalan (Mel) are currently widely used in elderly patients undergoing Allo-HCT. Nevertheless, the post-transplant relapse rate remains as high as 30%-55%, and the long-term GVHD-free and Relapse-free Survival (GRFS) rate fluctuates between 21% and 59%, suggesting that the efficacy of transplantation needs to be further improved. Further comparison of the commonly used RIC regimens in elderly patients-namely Flu+Bu (2-day), Flu+Bu (4-day) and Flu+Mel-has demonstrated that the Flu+Mel regimen yields superior transplantation outcomes over the Flu+Bu regimens.\n\nAt present, the optimal RIC regimen for elderly patients with hematological malignancies has not yet been clearly defined. The selection of transplantation conditioning regimens for elderly patients should strike a balance between reducing non-relapse mortality and decreasing post-transplant relapse. Over the past 20 years, an increasing number of targeted drugs acting on specific cellular signaling pathways, anti-apoptotic proteins, epigenetic regulators, and monoclonal antibodies have been introduced into clinical practice, thereby revolutionizing the treatment landscape of hematological malignancies. These novel targeted therapies not only bring hope of achieving remission to patients with hematological tumors resistant to traditional chemotherapy, but also the combined application of novel drugs and Allo-HCT is bound to fundamentally transform the overall technical system of hematopoietic stem cell transplantation. Venetoclax is a potent and selective oral inhibitor targeting the BH3 domain of the anti-apoptotic protein Bcl-2. In 2018, the FDA approved Venetoclax as a first-line induction chemotherapy agent for elderly AML patient's ineligible for intensive chemotherapy, with a complete remission rate of up to 67% and favorable tolerability¹¹. Preclinical studies using Allo-HCT animal models have confirmed that the addition of a Bcl-2 inhibitor to RIC regimens can promote donor cell engraftment, reduce the incidence of GVHD, without impairing the graft-versus-leukemia (GVL) effect¹². In recent years, clinical trials have reported the efficacy and safety of the conditioning regimen combining Venetoclax with Flu+Bu in patients with myeloid malignancies undergoing Allo-HCT. Our research center has demonstrated the favorable safety profile and promising long-term survival outcomes of the Venetoclax plus Flu+Mel conditioning regimen in a phase II clinical trial involving patients aged over 50 years with AML\u002FMDS undergoing Allo-HCT (2024 EBMT Poster B093; 2025 EBMT Poster B126). However, the long-term superiority of this novel regimen over the conventional Flu+Mel conditioning regimen remains to be clarified.\n\nTherefore, based on the existing findings from clinical studies and Allo-HCT animal model research, we hypothesize that incorporating Venetoclax into the Fludarabine+Melphalan conditioning regimen for elderly patients undergoing Allo-HCT is expected to improve long-term post-transplant survival and further enhance the transplantation efficacy in this patient population.",[167,168,169,26,170,171],"Venentoclax","Myeloid Malignancies","Conditioning","Acute Myeloid Leucemia","Myeldysplastic Syndrome (MDS)","2026-03-16",{"date":174,"type":31},"2026-03-17",{"date":176,"type":20},"2026-03-01",{"date":178,"type":20},"2030-06-30",{"name":180,"class":38},"First Affiliated Hospital of Zhejiang University",18,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":190,"targetDuration":4,"studyType":50,"phases":192,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":209,"locationsCount":39},"100518306","phase-2-risk-adapted-conditioning-regimen-for-allogeneic-hematopoietic-stem-cell-transplantation-100518306","NCT06028828","Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation","Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)","ADAPT","Inclusion Criteria:\n\n1. Male or female aged 18-70 years\n2. Diagnosis of AML, ALL, MDS, CML, NHL, HD, CLL requiring AHSCT\n3. Has an HLA-matched related (MRD), HLA-matched unrelated (MUD), haploidentical (HAPLO) or 1-Ag mismatched unrelated donor (MMUD)\n4. Karnofsky performance \\>70%\n5. Adequate major organ system function as demonstrated by:\n\n   1. Serum creatinine clearance equal or more than 50 ml\u002Fmin (calculated with Cockroft-Gault formula).\n   2. Bilirubin equal or less than 1.5 mg\u002Fdl except for Gilbert's disease. ALT or AST equal or less than 200 IU\u002Fml for adults. Conjugated (direct) bilirubin less than 2x upper limit of normal.\n   3. Left ventricular ejection fraction equal or greater than 40%.\n   4. Diffusing capacity for carbon monoxide (DLCO) equal or greater than 50% predicted corrected for hemoglobin.\n6. Ability to understand and the willingness to sign a written informed consent. a. Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial.\n\nExclusion Criteria:\n\n1. Inability to comply with medical recommendations or follow-up\n2. Pregnancy\n3. Active\u002Funcontrolled bacterial or viral infection (PI is the final arbiter of this criterion.)\n4. Has active CNS or ocular disease involvement within 3 months\n5. Patients with primary CNS lymphoma\n6. Patients who require modifications of the conditional regimen",{"count":191,"type":20},60,[81],"This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.",[55,195,196],"Allogeneic Stem Cell Transplantation","Hematologic Malignancies",[55,198,199,200,201,202],"Allogeneic Stem Cell transplantation","AHSCT","Hematologic malignancies","Melphalan","Hematopoietic stem cell transplant -composite risk","2026-01-29",{"date":205,"type":31},"2026-02-02",{"date":207,"type":31},"2023-09-11",{"date":93,"type":20},{"name":210,"class":38},"University of California, Irvine",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":4},"100617874","perianal-mbl-cre-colonization-and-infection-in-allogeneic-hematopoietic-stem-cell-transplant-patients-100617874","NCT07324291","Perianal MBL-CRE Colonization and Infection in Allogeneic Hematopoietic Stem Cell Transplant Patients","Prospective Cohort Study of Perianal MBL-CRE Colonization and Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients","Inclusion Criteria:\n\n* Adult patients (≥18 years) who received allogeneic hematopoietic stem cell transplantation;\n\nExclusion Criteria:\n\n* Engraftment failure.",{"count":219,"type":20},1000,"The goal of this observational study is to characterize the clinical features of metallo-β-lactamase-producing carbapenem-resistant Enterobacterales (MBL-CRE) colonization and subsequent infection in patients after allogeneic hematopoietic stem cell transplantation (HSCT). The study aims to estimate the incidence of perianal MBL-CRE colonization, the proportion of subsequent infections, the associated risk factors, mortality, and the underlying antibiotic resistance mechanisms.\n\nThe main questions this study seeks to answer are:\n\n1. What is the incidence of perianal MBL-CRE colonization following allogeneic HSCT?\n2. Among colonized patients, what proportion subsequently develop MBL-CRE infections?\n3. What are the risk factors for colonization and infection, the patterns of antimicrobial resistance, and the mortality among infected patients? Participants will undergo perianal swab screening for CRE as part of their routine post-transplant care. MBL-CRE isolates identified from perianal swabs will undergo antimicrobial resistance genomic analysis to investigate bacterial transmission dynamics and resistance mechanisms.",[26,222],"Carbapenem-resistant Enterobacterales","2025-12-23",{"date":225,"type":31},"2026-01-07",{"date":227,"type":20},"2026-01",{"date":229,"type":20},"2027-06",{"name":231,"class":38},"Institute of Hematology & Blood Diseases Hospital, China",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":239,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":242,"conditions":243,"keywords":252,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":4},"100605065","cardiovascular-complications-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-100605065","NCT07157670","Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.","ALLOCARDIOTOX","Inclusion Criteria:\n\n* Age ≥ 15 years\n* Informed about the study and without objection to participation (or with consent from legal guardians)\n* Undergoing allogeneic HSCT\n\nExclusion Criteria:\n\n* Patient not followed up at the participating center\n* Pregnant or breastfeeding women\n* Patient not affiliated with social security\n* Patient under guardianship, curatorship, or legal protection","15 Years",{"count":241,"type":20},400,"Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year. Conditioning and maintenance regimens carry a risk of both short- and long-term cardiotoxicity, leading to serious cardiovascular events including acute coronary syndrome (ACS), cardiac dysfunction, arrhythmias, pulmonary hypertension, and pericardial effusion. The pathophysiology of cardiotoxicity in HSCT patients remains poorly understood.\n\nIt is therefore crucial to investigate underlying mechanisms and identify predictive factors of cardiotoxicity in order to provide appropriate cardiological follow-up and management. Current European Society of Cardiology guidelines recommend routine monitoring of HSCT patients with echocardiography and cardiac biomarkers (NT-proBNP, troponin), although these recommendations are based on small-scale studies. The cardiodepressor factor DPP3 has shown promising results in cardio-oncology, with a causal role in anthracycline-induced cardiac dysfunction. Its role in HSCT-related cardiotoxicity requires further evaluation.\n\nThis multicenter study of HSCT recipients will be a valuable resource, enabling a better understanding of the pathophysiology of cardiotoxicity and prognosis. It will highlight imaging (echocardiography, calcium score, supra-aortic Doppler), electrocardiographic, and biological markers (including DPP3) associated with prognosis.",[244,245,246,55,247,248,249,250,251],"Cardiotoxicity","DPP3","HSCT","ACS - Acute Coronary Syndrome","Cardiac Dysfunction","Arrythmia, Cardiac","Pulmonary Hypertension","Machine Learning",[245,246,244,253,251],"Allogeneic hematopoietic stem cell transplantation","2025-09-02",{"date":256,"type":31},"2025-09-05",{"date":258,"type":20},"2025-09-15",{"date":260,"type":20},"2028-09-15",{"name":262,"class":38},"Assistance Publique - Hôpitaux de Paris",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":50,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":4},"100604118","virtual-reality-intervention-for-symptom-management-in-stem-cell-transplantation-100604118","NCT07145359","Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation","Development and Evaluation of A Virtual Reality Intervention for Symptoms Management During Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Able to speak and understand Turkish\n* Scheduled to undergo allogeneic hematopoietic stem cell transplantation (HSCT)\n* Receiving stem cell products collected from peripheral blood\n* Voluntarily agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* Undergoing autologous hematopoietic stem cell transplantation\n* Receiving stem cell products collected from bone marrow\n* Diagnosed with medical or psychiatric comorbidities that could interfere with participation, as reported by the healthcare team\n* Presenting infection symptoms (e.g., respiratory, gastrointestinal) that may contaminate study equipment, as identified by the healthcare team\n* Having visual, auditory, verbal, or cognitive impairments that may prevent interaction with the VR equipment\n* Previously received any form of hematopoietic stem cell transplantation",{"count":271,"type":20},30,[136],"The goal of this clinical trial is to evaluate whether a virtual reality (VR) intervention based on the Symptom Management Model can reduce physical and psychosocial symptoms during hematopoietic stem cell transplantation (HSCT) in adult patients undergoing allogeneic transplantation.\n\nThe main questions it aims to answer are:\n\nDoes the VR intervention reduce distress levels during HSCT?\n\nDoes the VR intervention decrease state anxiety and symptom severity compared to standard care?\n\nDoes the VR intervention positively affect physiological outcomes and engraftment times?\n\nResearchers will compare a group receiving standard clinical care plus a VR nature-themed video during HSCT to a group receiving standard care only to see if the VR intervention improves symptom management outcomes.\n\nParticipants will:\n\nBe randomly assigned to either the intervention or control group.\n\nIn the intervention group:\n\nWatch a 15-minute nature-themed VR video during stem cell infusion using Meta Quest 3.\n\nThe video content will be specifically created by the research team based on the principles of Attention Restoration Theory (ART).\n\nIn both groups:\n\nComplete pre- and post-intervention assessments including:\n\nDistress Thermometer\n\nState-Trait Anxiety Inventory\n\nEdmonton Symptom Assessment Scale\n\nPhysiological measures (vital signs)\n\nEngraftment tracking\n\nSatisfaction and open-ended feedback forms",[275,276,277,278,279,26],"Cancer and \u002F or Hematological Malignancy","Hematopoetic Stem Cell Transplantation","Nursing Interventions","Symptom Management","Virtual Reality","2025-08-21",{"date":282,"type":31},"2025-08-28",{"date":284,"type":20},"2025-09-10",{"date":286,"type":20},"2026-09-10",{"name":288,"class":38},"Halic University",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":296,"maxAge":17,"enrollmentInfo":297,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":299,"conditions":300,"keywords":304,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":312,"leadSponsor":314,"locationsCount":39},"100593971","immunoglobiulin-specific-prophylaxis-of-citomegalovirus-infections-in-immunocompromised-children-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-100593971","NCT07013370","Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","Immunoglobulin-specific Prophylaxis Against Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Children who underwent allogeneic HSCT due to any condition\n\nExclusion Criteria:\n\n* Positive personal records of immunoglobulin-related adverse reactions\n* CMV reactivation before the CMV-specific immunoglobulin prophylaxis onset\n* adoptive cellular post-HSCT immunotherapy for any indication","1 Month",{"count":298,"type":20},150,"Human cytomegalovirus (CMV) is a globally prevalent, human-specific herpesvirus characterised by a lifelong latency after primary infection, an often asymptomatic reactivation and affecting up to 100% of adults based on region and age. CMV reactivation has serious risks for immunocompromised patients, especially those undergoing allogeneic hematopoietic stem cell transplantation (HSCT). In these patients, CMV can lead to graft failure, multiorgan disease, increased risk of other infections, GVHD, post-transplant lymphoproliferative disorders, and higher transplant-related mortality (TRM). Although antiviral prophylaxis, CMV infection occurs in 38-80% of HSCT recipients, but current antiviral drugs are insufficiently effective and they are associated with adverse effects. Furthermore, treatment failure is due to the high genetic variability of CMV. The protective role of virus-specific antibodies remains under debate. Some studies suggest that high neutralizing antibody titers protect transplant recipients from CMV, while others highlight the importance of T-cell responses. However, recent animal studies showed that humoral immunity alone can prevent CMV reactivation, even without T or NK cells. In solid-organ transplant patients, antibody titers ≥480 have been linked to reduced infection, shorter treatment, and full protection from CMV disease. Although the use of anti-CMV immunoglobulin remains controversial, the IRCCS Burlo Garofolo has used it as post-transplant prophylaxis and second-line treatment for over a decade.\n\nThe main objective of their study was to assess whether CMV-specific immunoglobulin prophylaxis reduces CMV incidence and severity in pediatric HSCT patients. Secondary goals included evaluating its effect on transplant outcomes and its efficacy across different ethnic groups. A population pharmacokinetic (POP\u002FPK) study was also conducted to better understand the drug's distribution and elimination and to identify factors influencing its pharmacokinetics in patients.",[301,302,55,303],"Immunoglobulin Prophylaxis","Cytomegalovirus Infections","Transplant-Related Disorder",[305,306,307],"Cytomegalovirus","allo-HSCT","Transplant-Related mortality","2025-06-02",{"date":310,"type":31},"2025-06-10",{"date":308,"type":31},{"date":313,"type":20},"2026-06-02",{"name":315,"class":38},"Antonello Di Paolo, M.D., Ph.D.",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":16,"minAge":324,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":327,"conditions":328,"keywords":331,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":39},"100588841","geriatric-assessment-ga-for-elderly-patients-undergoing-allo-hsct-100588841","NCT06946654","Geriatric Assessment (GA) for Elderly Patients Undergoing Allo-HSCT","Geriatric Assessment (GA) for Elderly Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Prospective Study.","GA","Inclusion Criteria:\n\n* (a)Age ≥55 years.\n* (b)Hematologic disorders with established indications for transplantation, including malignant and non-malignant hematologic diseases. (c)Willingness to provide informed consent.\n\nExclusion Criteria: (a)Pregnancy. (b) Uncontrolled active infection. (c) Lack of informed consent. (d)Deemed ineligible for transplantation after investigator assessment","55 Years",{"count":326,"type":20},176,"This comprehensive, multidimensional evaluation assesses patient-related factors, disease-related factors, donor-related factors, and treatment-related factors. The study aims to identify potential risk factors influencing transplant outcomes in elderly patients and enhance the outcomes of allo-HSCT.",[329,330,26],"Elderly","Geriatric Assessment",[332,330,306],"elderly","2025-05-09",{"date":335,"type":31},"2025-05-11",{"date":337,"type":20},"2025-05-20",{"date":339,"type":20},"2027-03-31",{"name":123,"class":38},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":324,"enrollmentInfo":348,"targetDuration":4,"studyType":50,"phases":350,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":39},"100568813","phase-2-demethylating-agents-combined-with-venetoclax-for-high-risk-t-cell-lymphoblastic-lymphomaleukemia-post-transplant-relapse-prevention-100568813","NCT06686108","Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma\u002FLeukemia Post-Transplant Relapse Prevention","Safety and Efficacy Study of Demethylating Agents With Venetoclax in Preventing Recurrence of High-risk T-cell Lymphoblastic Lymphoma\u002FLeukemia After Transplantation","Inclusion Criteria:\n\n* 1.14-55 years old, male,or female.\n* 2.Patients with allo-HSCT due to T-LBL\u002FALL, the donor type is not limited.\n* 3.ECOG score is 0-2 points.\n* 4.Blood routine: ANC ≥ 1.0 × 109\u002FL, PLT ≥ 50 × 109\u002FL.\n* 5.One of the following high-risk factors:\n* a. Age of initial diagnosis ≥ 35 years old.\n* b. Initial diagnosis of WBC ≥ 100 × 109\u002FL.\n* c. Initial diagnosis of LDH exceeding the upper limit of normal values.\n* d. Initial diagnosis of bone marrow involvement (blast cells ≥ 5%).\n* e. Initial diagnosis of a bulky in the mediastinum (longest diameter ≥ 10cm).\n* f. ETP immunophenotype.\n* g. During the induction chemotherapy process, 2 courses did not achieve partial remission and\u002For 4 courses did not achieve complete remission.\n* h. Residual lesions before transplantation: Flow cytometry analysis showed that the proportion of abnormal lymphoid cells in the bone marrow was greater than 0.01%; Positive detection of minimal residual lesions in molecular biology; PET-CT scan shows that residual lesions are still active.\n* i. Based on the ELN recommendation based on adult T-ALL: gene mutations involving myeloid related genes, RAS\u002FPI3K\u002FAKT, JAK\u002FSTAT signaling pathway, and epigenetics, such as FLT3, NRAS\u002FKRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations; t (8; 14) (q24; q11)\u002FMYC rearrangement; t (7; 19) (q34; p13)\u002FTCR-LYL1，TCR-MEF2C; del(5q) (q14).\n* j. High risk subgroups based on NGS definition: PI3K signaling pathway\u002FNRAS, KRAS\u002FTP53\u002FIKZF1\u002FDNTM3A\u002FIDH1, IDH2 gene mutation with or without NOTCH1, FBXW7\u002FPHF6\u002FEP300 gene mutation.\n\nExclusion Criteria：\n\n* 1.Central involvement during any course of the disease.\n* 2.Patients who have not achieved complete remission before transplantation.\n* 3.Identify those with available targeted drugs.\n* 4.For those who are resistant to BCL-2 inhibitors before transplantation, if the disease progresses during the application process, or if 3-4 courses of induction therapy containing BCL2 inhibitors do not improve.\n* 5.Individuals who are known to be allergic to demethylating drugs or venetoclax.\n* 6.Individuals with grade 2 or more degrees of active acute GVHD.\n* 7.Individuals with moderate to severe chronic GVHD.\n* 8.T-LBL\u002FALL relapse (flow cytometry abnormal lymphocyte cell proportion\\>0.01%, WT1 positive, fusion gene positive, or extramedullary recurrence), or transplant rejection, bone marrow donor cell chimerism\\\u003C95%.\n* 9.Blood routine: ANC\\\u003C1.0 × 109\u002FL or PLT\\\u003C50 × 109\u002FL.\n* 10.Combined with severe organ dysfunction; The ratio of aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) is more than 3 times the normal value or the normal value of direct bilirubin is more than 3 times; The endogenous creatinine clearance rate (Ccr) is less than 50mL\u002Fmin or 1.5 times the normal value of blood creatinine, regardless of whether hemodialysis treatment is used.\n* 11.Merge severe active infections.\n* 12.Pregnant or lactating women.\n* 13\\. Accepting other investigational drugs.\n* 14.According to the researchers' assessment, the patient may have complications that could lead to other dangers.",{"count":349,"type":20},59,[81],"This study is a prospective, phase II clinical trial with the primary objective of assessing the effectiveness of demethylating agents combined with venetoclax in the prevention of recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) of high risk T-lymphoblastic lymphoma\u002Fleukemia (T-LBL\u002FALL) patients.",[353,26,354],"T-cell Acute Lymphoblastic Leukemia","Relapse",[356,357,358],"T-cell lymphoblastic lymphoma\u002Fleukemia","relapse","allogeneic hematopoietic stem cell transplantation","2025-05-04",{"date":361,"type":31},"2025-05-07",{"date":363,"type":31},"2024-10-30",{"date":365,"type":20},"2028-10-30",{"name":367,"class":38},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":389},"100570230","abnormal-glucose-tolerance-in-allogeneic-hematopoietic-stem-cell-transplantation-100570230","NCT06704542","Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation","A Study of the Impact of Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation Donors on Recipients' Post-Transplant Survival Outcomes: A Multicenter Retrospective Cohort Study Based on HIS Data","Inclusion Criteria:\n\n* Patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between March 2019 and March 2024;\n* Donor had fasting blood glucose and\u002For HbA1c records\n* Eastern Cooperative Oncology Group (ECOG) physical fitness score of 0-2\n* Survived at least 12 weeks after HSCT\n* Voluntarily signed the Informed Consent Form\n* Had appropriate organ function;\n* Laboratory results within 7 days prior to HSCT met the following criteria:\n\n  1. Aspartate aminotransferase (AST) ≤ 3-fold (upper limit of norma, ULN);\n  2. Alanine aminotransferase (ALT) ≤ 3x ULN;\n  3. Total serum bilirubin ≤ 1.5 times the upper limit of normal ULN unless the patient has documented Gilbert syndrome; patients with Gilbert-Meulengracht syndrome with bilirubin ≤ 3.0 times the upper limit of normal and direct bilirubin ≤ 1.5 times the upper limit of normal may be included;\n  4. Serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 60 mL\u002Fmin;\n  5. Coagulation function: International Normalized Ratio (INR) ≤1.5×ULN, Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN;\n\nExclusion Criteria:\n\n* Active autoimmune diseases such as SLE, rheumatoid arthritis, etc.\n* Active cardiovascular disease such as uncontrolled arrhythmias, uncontrolled hypertension, congestive heart failure, any Grade 3 or 4 heart disease as determined by the New York Heart Association (NYHA) Functional Class, or a history of myocardial infarction in the 6 months prior to screening;\n* Other serious medical conditions that may limit the patient's participation in this trial (e.g., progressive infection, uncontrolled diabetes);\n* HIV infection, or chronic infection with hepatitis B virus (HBsAg-positive) or hepatitis C virus (anti-HCV-positive) that cannot be controlled by medications;\n* Patients with other uncured tumors\n* Patients with neurological or psychiatric disorders\n* Patients who were unable to understand or comply with the research protocol or are unable to sign the Informed Consent Form",{"count":219,"type":20},"To investigate the impact of abnormal glucose tolerance in hematopoietic stem cell transplantation donors on patients' post-transplant survival outcomes.",[26,378,379],"Diabetes Mellitus","Impaired Fasting Glucose","2024-11-24",{"date":382,"type":31},"2024-11-26",{"date":384,"type":20},"2024-11",{"date":386,"type":20},"2025-04",{"name":388,"class":38},"Ruijin Hospital",6,{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":407},"100570506","allogeneic-hematopoietic-stem-cell-transplantation-cohort-study-100570506","NCT06708130","Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study","Inclusion Criteria:\n\n1. At least one visit to a stem cell transplant center beginning January 1, 2021\n2. Proposed to undergo or have undergone hematopoietic stem cell transplantation\n\nExclusion Criteria:\n\n1. Long-term follow-up information for patients not available for any reason (e.g., unavailable or with serious concomitant disease) according to investigator opinion\n2. Due to alcohol and drug addiction thus affecting their ability to follow the requirements of the study\n3. Presence of conditions that could jeopardize patient safety or affect their adherence to the protocol, according to the investigator's opinion",{"count":397,"type":20},3000,"Clinical observational studies using epidemiologic theories and methods. Through the collection of various clinically relevant data, specific outcomes are evaluated in hematologic transplant patients, providing high quality real-world data for clinical practice, informing public health decision-making, and reducing the burden of disease",[55],{"date":401,"type":31},"2024-11-27",{"date":403,"type":31},"2021-05-01",{"date":405,"type":20},"2031-12-31",{"name":388,"class":38},3,{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":16,"minAge":415,"maxAge":324,"enrollmentInfo":416,"targetDuration":4,"studyType":50,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":39},"100567843","phase-3-bucy-vs-tbicy-for-allo-hsct-in-t-all-patients-100567843","NCT06673459","BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients","Busulfan Plus Cyclophosphamide Vs. Total Body Irradiation Plus Cyclophosphamide for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute T Lymphoblastic Leukemia: a Randomized Controlled, Open-label, Multi-center Clinical Trial","Inclusion Criteria:\n\n1. T-ALL patients aged \\> 2 years and ≤55 years;\n2. For the first time accept allo-HSCT;\n3. With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3; 4. Signing an informed consent form, having the ability to comply with study and follow-up procedures.\n\nExclusion Criteria:\n\n1. With other malignancies;\n2. With a previous history of autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation or chimeric antigen receptor T cell therapy;\n3. With uncontrolled infection intolerant to haploidentical hematopoietic cell transplantation;\n4. With severe organ dysfunction;\n5. In pregnancy or lactation period;\n6. With any conditions not suitable for the trial (investigators' decision).","2 Years",{"count":417,"type":20},430,[164],"T-cell acute lymphoblastic leukemia (T-ALL), a hematological malignant neoplasm of immature T cells, accounting for a morbidity of 10-15% among pediatric and 20-25% among adult patients of ALL. Despite the application of improved intensive therapies, the overall survival (OS) of T-ALL patients is still unsatisfactory, with a 5-year OS rate of less than 60% in adults and 85% in children. Over the past few decades, allogeneic hematopoietic stem-cell transplantation (allo-HSCT) has emerged as a potential and the most likely curative treatment for patients with high-risk hematological malignant neoplasms, and it has been proven that allo-HSCT could hold the potential to improve the prognosis of T-ALL patients and may even cure T-ALL.\n\nThe two most common myeloablative conditioning regimens for T-ALL patients with allo-HSCT were total body irradiation (TBI) plus cyclophosphamide (TBI-Cy) and busulfan (Bu) plus cyclophosphamide (BuCy). The most common use conditioning regimen for ALL patients is the TBI-Cy conditioning regimen over other hematological malignancy patients because TBI possess potent and distinct anti-leukemic effects, particularly in organs not easily affected by systemic chemotherapy and intense immunosuppressive effects. However, TBI-based conditioning regimens may cause a high risk of cataracts, interstitial pneumonitis (IP), engraftment failure and even subsequent malignant neoplasms (SMNs). To avoid these disadvantages, intravenous Bu replaced TBI as a part of conditioning.\n\nExtensive studies have shown that allo-HSCT with conditioning regimens based on TBI could benefit survival compared with conditioning regimens based on chemotheraphy in treating ALL. We retrospectively analyzed post-10-year data from T-ALL patients from two transplant centers, and all the databases were used to eliminate confounding factors via PSM. We demonstrated that the TBI-Cy conditioning regimen had inferior efficacy to the BuCy conditioning regimen, especially for T-ALL patients who were children, refractory, had extramedullary disease before transplantation, had active disease or an MRD-positive status at allo-HSCT, or who received haplo-HSCT.",[421,26,422,423],"T-Cell Lymphocytic Leukemia","Total Body Irradiation","Chemotherapy","2024-11-02",{"date":426,"type":31},"2024-11-05",{"date":428,"type":20},"2024-12-01",{"date":430,"type":20},"2029-11-30",{"name":37,"class":38},{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":39},"100464436","impact-of-the-use-of-allogeneic-hematopoietic-stem-cell-transplantation-in-reunion-island-patients-quality-of-life-determinants-of-choices-and-financial-repercussions-100464436","NCT05327673","Impact of the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Reunion Island Patients: Quality of Life, Determinants of Choices and Financial Repercussions","AlloRé","Inclusion Criteria:\n\n* patients diagnosed with hematological malignancy (myeloid acute leukemia, lymphoid acute leukemia, non-hodgkin lymphoma, Hodgkin disease, or myelodysplasic syndrome\n* candidate to an allogeneic hematopoietic stem cell transplantation in mainland France ;\n* Residing in Reunion Island\n* Age \\>18 year old;\n* who accept or not allogeneic hematopoietic\n* Able to complete a questionnaire\n\nExclusion Criteria:\n\n* Opposition to participation and collection of their data\n* Person deprived of liberty by judicial or administrative decision, and person subject to legal protection (guardianship or curators)",{"count":440,"type":20},100,"This project aims to document and analyse - with a three-fold anthropological, psychosocial and economical approach - the consequences of the geographical distance from mainland France on the alloSCT on both patients, their caregivers and the healthcare system. It is organised in 3 working packages (WP).",[55],"2022-04-14",{"date":445,"type":31},"2022-04-21",{"date":447,"type":20},"2022-07",{"date":449,"type":20},"2027-03",{"name":451,"class":38},"Centre Hospitalier Universitaire de la Réunion",{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":16,"minAge":460,"maxAge":104,"enrollmentInfo":461,"targetDuration":4,"studyType":50,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":4},"100448955","phase-2-haploidentical-allogeneic-hematopoietic-stem-cell-transplantation-with-post-transplant-cyclophosphamide-for-rescuing-patients-with-graft-failure-100448955","NCT05126186","Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure","Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure: a Phase II Study","HaploRescue","Inclusion Criteria:\n\n* Aged from 3 to 70 years\n* All hematological diseases\n* Suffering from primary or secondary (within the 60 days post-transplantation) graft failure after a 1st allo-SCT\n* With usual criteria for allo-SCT:\n\n  * ECOG ≤ 2\n  * No severe and uncontrolled infection\n  * Cardiac function compatible with high dose of cyclophosphamide\n  * Adequate organ function: ASAT and ALAT ≤ 2.5N, total bilirubin ≤ 2N, creatinine clearance ≥30ml \u002F min\n* With identification of a haploidentical donor (brother, sister, parents, adult children or cousin)\n* Absence of donor specific antibody (DSA) detected in the patient with a MFI ≥ 1500 (antibodies directed towards the distinct haplotype between donor and recipient)\n* With health insurance coverage (bénéficiaire ou ayant droit).\n* Understand informed consent or optimal treatment and follow-up.\n* Contraception methods must be prescribed during all the duration of the research. Women and men of childbearing age must use contraceptive methods within 12 months and 6 months after the last dose of cyclophosphamide, respectively.\n* Having signed a written informed consent (2 parents for patients aged less than 18)\n\nExclusion Criteria:\n\n* Aged\\\u003C 3 years old and \\>70 years old\n* With uncontrolled infection\n* With Seropositivity for HIV or HTLV-1 or active hepatitis B or C defined by a positive PCR HBV or HCV and associated hepatic cytolysis\n* Yellow fever vaccine within 2 months before transplantation\n* Cancer in the last 5 years (except basal cell carcinoma of the skin or \"in situ\" carcinoma of the cervix)\n* Uncontrolled coronary insufficiency, recent myocardial infarction \\\u003C6 month, current manifestations of heart failure, uncontrolled cardiac rhythm disorders, ventricular ejection fraction \\\u003C50%\n* Heart failure according to NYHA (II or more)\n* Preexisting acute hemorrhagic cystitis\n* Renal failure with creatinine clearance \\\u003C 30ml \u002F min\n* Urinary tract obstruction\n* Pregnant (β-HCG positive) or breast-feeding\n* Who have any debilitating medical or psychiatric illness, which preclude understanding the inform consent as well as optimal treatment and follow-up\n* COVID vaccination or recent COVID disease \\\u003C3 months\n* Tutorship or curatorship\n* Contraindications to treatments used during the research","3 Years",{"count":462,"type":20},35,[81],"Prognosis of patients with graft failure is dismal, and re-transplantation is the sole option for long-term survival. Currently, there is no consensus concerning therapeutic options in patients with primary or secondary (within the 60 days post-transplantation) graft failure and finding a new donor within an acceptable delay is challenging. Literature is poor on the subject while the overall survival of such patients is about 30% at 1 year. This situation thus represents today a very challenging unmet medical need.\n\nRecently, haploidentical (haplo) related donor Stem Cell Transplantation (haplo-SCT) have improved dramatically outcomes using T-cell replete grafts with administration of post-transplantation cyclophosphamide (PTCy, which targets alloreactive T cells generated early after an HLA-mismatched transplant, sparing regulatory T cells and leaving unaffected the non-dividing hematopoietic stem cells) and standard post-transplant immune suppression with a calcineurin inhibitor (CNI) and mycophenolate mofetil. Our group re-transplanted a patient who experienced two consecutive graft failures and was successfully managed through a third haplo-SCT from her son using PTCy. We then retrospectively collected and analyzed data from 26 primary graft failure patients transplanted between 2011 and 2017 in 15 centers on behalf of French Society for Stem Cell Transplantation and Cell Therapy (SFGM-TC). The study population consisted mainly of patients with primary or secondary (within the 60 days post-transplantation) graft failure who underwent haplo-SCT and received PTCy as graft-versus-host-disease prophylaxis. The 1-year overall survival was about 60% suggesting that this approach might be a valid option in this particular poor clinical situation but now need validation through a phase II multicenter, national, prospective cohort study.",[466,467,55],"Hematologic Diseases","Graft Failure","2021-11-08",{"date":470,"type":31},"2021-11-18",{"date":472,"type":20},"2021-12-01",{"date":474,"type":20},"2026-12-01",{"name":262,"class":38},{"id":477,"slug":478,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":50,"phases":485,"briefSummary":486,"conditions":487,"keywords":488,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":39},"100313186","determination-of-factors-involved-in-the-regulation-of-immune-responses-after-allogeneic-hematopoietic-stem-cell-transplantation-100313186","NCT03357172","Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation","REAL-GREFFE","Inclusion Criteria:\n\n* patient of the Nancy CHRU, for whom a CSH allograft is planned. or\n* hematopoietic stem cell donors received at Nancy's CHRU for the duration of the research\n\nExclusion Criteria:\n\n* Positive HIV\n* active hepatitis B or C infection",{"count":484,"type":20},700,[136],"The study concerns donors and patients receiving allogeneic stem cell haematopoietic transplantation. The aim of the study is to analyse HSC graft content in immune effector T (naive, memory, activated, exhausted) and immunoregulatory cell subtypes (Tregs, iNKT, MDSC) and correlate the results with post-transplant immune reconstitution of those different cell subtypes and clinical events (graft-versus-host-disease, relapse, infections). An ancillary study will focus on the impact of microbiota dysbiosis on post-transplant immune response and regulatory cell subsets.",[55],[489,490,491,492],"Immune recovery","Immunomodulatory cells","GVHD","GVL","2019-10-10",{"date":495,"type":31},"2019-10-14",{"date":497,"type":31},"2019-10-01",{"date":499,"type":20},"2026-09-30",{"name":501,"class":38},"Central Hospital, Nancy, France"]